Key result
Sleeve gastrectomy resulted in diabetes resolution in 80% of morbidly obese patients with type 2 diabetes at 18 months, compared to 0% with conventional medical therapy.
Why the study?
Does sleeve gastrectomy improve type 2 diabetes and obesity-related comorbidities in morbidly obese patients compared to conventional medical therapy?
Cohort (n=60)
No
Does sleeve gastrectomy improve type 2 diabetes and obesity-related comorbidities in morbidly obese patients compared to conventional medical therapy?
Sleeve gastrectomy is highly effective in resolving type 2 diabetes and improving obesity-related comorbidities compared to conventional medical therapy in morbidly obese patients.
Answers are grounded in this paper and cite their sources.
May support sleeve gastrectomy consideration in morbid obesity with diabetes; leaves open confirmation by randomized trials before practice change.
OBJECTIVE: To compare the effect of sleeve gastrectomy vs medical therapy on type 2 diabetes mellitus and other obesity-related comorbidities (obstructive sleep apnea syndrome, hypertension, and dyslipidemia) in prospectively enrolled and matched obese patients with type 2 diabetes. DESIGN: A prospective cohort study. Morbidly obese patients with type 2 diabetes who either underwent sleeve gastrectomy or conventional therapy were followed up and assessed for their diabetic state and other comorbidities every 3 months for 18 months. SETTING: Centre for the Surgical-Medical Treatment of Morbid Obesity, Policlinico “Umberto I,” University of Rome “Sapienza,” Italy. PATIENTS: A total of 30 morbidly obese patients with type 2 diabetes who underwent sleeve gastrectomy (group A) and a total of 30 morbidly obese patients with type 2 diabetes who underwent conventional therapy (group B). RESULTS: In group A, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 41.3 (6.0), 166.6 (68.1) mg/dL, and 7.9% (2.1%), respectively, and, at 18 months, these values were 28.3 (5.4), 96.2 (29.4) mg/dL, and 6.0% (1.5%), respectively. For 80% of patients, diabetes was resolved. With regard to other comorbidities, the prevalence of obstructive sleep apnea syndrome dropped from 50% to 10%, and patients reduced significantly their use of medication for hypertension and dyslipidemia. In group B, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 39.0 (5.5), 183.7 (63.5) mg/dL, and 8.1% (1.7%), respectively, and, at 18 months, these values were 39.8 (5.0), 150 (48) mg/dL, and 7.1% (1.3%), respectively. All patients remained diabetic and continued or increased their level of hypoglycemic therapy. With regard to other comorbidities, we observed an increase in the use of medication for hypertension and dyslipidemia, and the prevalence of obstructive sleep apnea syndrome did not change. CONCLUSIONS: This study confirms the efficacy of sleeve gastrectomy in the treatment of morbidly obese type 2 diabetic patients when compared with conventional medical treatment.
No takes yet. Share an insight, caveat, or question.
Leonetti et al. (2012) conducted a cohort in Morbid obesity and type 2 diabetes mellitus (n=60). Sleeve gastrectomy vs. Conventional medical therapy was evaluated on Resolution of diabetes. Sleeve gastrectomy resulted in diabetes resolution in 80% of morbidly obese patients with type 2 diabetes at 18 months, compared to 0% with conventional medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: